Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. Asia Pacific Biodefense Market, 2019-2030, $ mn 18
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Biodefense Market 19
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Biodefense Market 22
Figure 8. Investment Opportunity Analysis 26
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Biodefense Market 29
Figure 10. Breakdown of Asia Pacific Biodefense Market by Product, 2019-2030, % of Sales Revenue 33
Figure 11. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%) 34
Figure 12. Asia Pacific Biodefense Market: Vaccines, 2019-2030, $ mn 35
Figure 13. Asia Pacific Biodefense Market: Anthrax, 2019-2030, $ mn 38
Figure 14. Asia Pacific Biodefense Market: Smallpox, 2019-2030, $ mn 39
Figure 15. Asia Pacific Biodefense Market: Botulism, 2019-2030, $ mn 40
Figure 16. Asia Pacific Biodefense Market: Nuclear/Radiation, 2019-2030, $ mn 41
Figure 17. Asia Pacific Biodefense Market: E-Bola, 2019-2030, $ mn 42
Figure 18. Asia Pacific Biodefense Market: Zika, 2019-2030, $ mn 43
Figure 19. Asia Pacific Biodefense Market: Other Vaccines, 2019-2030, $ mn 44
Figure 20. Asia Pacific Biodefense Market: Biothreat Detection Devices, 2019-2030, $ mn 45
Figure 21. Asia Pacific Biodefense Market: Antibiotics, 2019-2030, $ mn 47
Figure 22. Asia Pacific Biodefense Market: Masks, 2019-2030, $ mn 48
Figure 23. Asia Pacific Biodefense Market: Other Products, 2019-2030, $ mn 49
Figure 24. Breakdown of Asia Pacific Biodefense Market by Sales Channel, 2019-2030, % of Sales Revenue 50
Figure 25. Asia Pacific Addressable Market Cap in 2020-2030 by Sales Channel, Value ($ mn) and Share (%) 51
Figure 26. Asia Pacific Biodefense Market: Online Sales, 2019-2030, $ mn 52
Figure 27. Asia Pacific Biodefense Market: Offline Sales, 2019-2030, $ mn 53
Figure 28. Breakdown of Asia Pacific Market by Application, 2019-2030, % of Revenue 54
Figure 29. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 55
Figure 30. Asia Pacific Biodefense Market: Military, 2019-2030, $ mn 56
Figure 31. Asia Pacific Biodefense Market: Civilian, 2019-2030, $ mn 57
Figure 32. Breakdown of APAC Biodefense Market by Country, 2019 and 2030, % of Revenue 59
Figure 33. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 60
Figure 34. Biodefense Market in Japan, 2019-2030, $ mn 62
Figure 35. Biodefense Market in China, 2019-2030, $ mn 64
Figure 36. Biodefense Market in Australia, 2019-2030, $ mn 66
Figure 37. Biodefense Market in India, 2019-2030, $ mn 68
Figure 38. Biodefense Market in South Korea, 2019-2030, $ mn 70
Figure 39. Biodefense Market in Rest of APAC, 2019-2030, $ mn 72
Figure 40. Growth Stage of Asia Pacific Biodefense Industry over the Forecast Period 74
Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact. Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Vaccines • Anthrax • Smallpox • Botulism • Nuclear/Radiation • E-Bola • Zika • Other Vaccines Biothreat Detection Devices • Detectors/Triggering Devices • Assays and Reagents • Samplers • Identifiers Antibiotics Masks Other Products Based on Sales Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Online Sales • Offline Sales Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Military • Civilian Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Achaogen, Inc. Alexeter Technologies LLC Alnylam Pharmaceuticals, Inc. Altimmune, Inc. Bavarian Nordic AS BioFactura, Inc. Cleveland Biolabs, Inc. Dynavax Technologies Inc Dynport Vaccine Company LLC (DVC) Elusys Therapeutics, Inc. Emergent BioSolutions Inc General Dynamics Corp. GlaxoSmithKline Plc Ichor Medical Systems Mediimmune (AstraZeneca) Nanotherapeutics, Inc. Ology Bioscience PathSensors Inc Pluristem Therapeutics Sanofi Pasteur Ltd. SIGA Technologies, Inc. Soligenix, Inc. Xoma Corporation (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More